Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

AI is revolutionizing industries, but misleading claims are rampant. Learn how the SEC combats AI washing and the importance of transparency for investment advisers.
Discover how the Inflation Reduction Act of 2022 boosts tax deductions for energy efficient commercial buildings with major incentives reaching up to $5 per sq. ft.
California’s governor has proposed temporarily suspending NOL deductions & limiting tax credits to $5 million for the next three years to address budget shortfalls.
Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.
Accounting for CCS projects is a nuanced challenge, especially concerning lease considerations under ASC 842. This article aims to illuminate these complexities.
Recent trends in financial performance & provider productivity show challenges facing medical groups related to practice margins. What does it mean for valuations?
Whether preceding an M&A transaction or another executive hire, due diligence identifies any red flags before inking a high-stakes deal.
Taxpayers who paid the Tennessee franchise tax under the “alternative minimum property measure” should determine whether they qualify for the refund.
Gain clarity about recent changes in the Texas franchise tax “no tax due” revenue threshold and more details about PIR/OIR extensions.
Recently, The Texas Higher Education Coordinating Board (THECB) released updates and clarifications to rules adopted in June 2023 for FY 2024. The updates apply to FY 2025 and include changes in four areas: Credentials of Value, Fundable Credentials, High-Demand Fields, and Methodology and Process Changes.
In any health care segment, buyer concentration can have an effect on valuation pricing and is one of the key macro-dynamics that should be considered in a health care valuation analysis.
The credit is aimed at bolstering and incentivizing the emerging biotechnology sector to create jobs and invest in NYC and is available 1/1/23-1/1/26.
1 14 15 16 17 18 19 20 177